Abstract:9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one (KY‐31) displayed relatively low toxicity and retained anti‐inflammatory activity with a higher selectivity index compared to 9‐aminacrine (9‐AA). It may exert its anti‐inflammatory effects through the nuclear receptor subfamily 4 group A member 1 (NR4A1)/Interleukin‐10 (IL‐10)/suppressors of cytokine signalling 3 (SOCS3) signaling pathway and inhibit the protein targets phosphodiesterase‐4 (PDE‐4) and p38 mitogen‐activated protein kinases (MAPK). These findings support further development and exploration of 9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one as a promising anti‐inflammatory compound for inflammatory conditions. 9‐aminacrine (9‐AA), an external antibacterial agent, possesses important bioactivities for the treatment of cancer, viruses, and prion diseases. Recent research has revealed that 9‐AA has anti‐inflammatory effects through the up‐regulation of nuclear receptor subfamily 4 group A member 1 (NR4A1), but it is highly cytotoxic. To mitigate its toxicity, three series of novel 9‐AA derivatives were synthesized. The toxicity of all compounds was assessed, and some of the less toxic compounds were tested for in vitro anti‐inflammatory activities, leading to the establishment of structure‐activity relationships. In particular, 9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one exhibited relatively low toxicity and retained anti‐inflammatory activity, with a higher selectivity index compared to 9‐AA (3.44 versus 0.68). Expression experiments of inflammatory mediators revealed that this compound not only inhibited the gene expression of pro‐inflammatory factors, but also promoted the gene expression of anti‐inflammatory factors. Preliminary mechanistic studies suggested that it exerted anti‐inflammatory effects through the NR4A1/Interleukin‐10 (IL‐10)/suppressors of cytokine signalling 3 (SOCS3) signaling pathway. Furthermore, molecular docking studies indicating that it may exhibit anti‐inflammatory activity by inhibiting the protein targets phosphodiesterase‐4 (PDE‐4) and p38 mitogen‐activated protein kinases (MAPK). Based on our data, 9‐amino‐8‐bromo‐3,4‐dihydroacridin‐1(2H)‐one with its low toxicity and anti‐inflammatory properties, holds promise for further development as an anti‐inflammatory agent.

Discovery of novel 2-aryl-4-bis-amide imidazoles (ABAI) as anti-inflammatory agents for the treatment of inflammatory bowel diseases (IBD)

Discovery of a New Anti-Inflammatory Agent from Anemoside B4 Derivatives and Its Therapeutic Effect on Colitis by Targeting Pyruvate Carboxylase

Discovery of Novel Imidazo[4,5- c ]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis

Design, synthesis, and bioactivity evaluation of novel amide/sulfonamide derivatives as potential anti-inflammatory agents against acute lung injury and ulcerative colitis

Discovery of novel N2-indazole derivatives as phosphodiesterase 4 inhibitors for the treatment of inflammatory bowel disease

Discovery of Novel 2‐(piperidin‐4‐yl)‐1h‐benzo[d]imidazole Derivatives As Potential Anti‐Inflammatory Agents

Discovery of a Series of 4-Amide-thiophene-2-carboxyl Derivatives As Highly Potent P2Y14 Receptor Antagonists for Inflammatory Bowel Disease Treatment

Discovery of 6‐Acylamino/Sulfonamido Benzoxazolone with IL‐6 Inhibitory Activity as Promising Therapeutic Agents for Ulcerative Colitis

Synthesis and SAR Study of Novel Diimide Skeleton Compounds with the Anti-Inflammatory Activities in Vitro and in Vivo.

Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases.

Structural Exploration, Synthesis and Pharmacological Evaluation of Novel 5-Benzylidenethiazolidine-2,4-dione Derivatives As Inos Inhibitors Against Inflammatory Diseases

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Discovery of acylated isoquercitrin derivatives as potent anti-neuroinflammatory agents in vitro and in vivo

Identification of novel indolinone derivatives as CTSC inhibitors to treat inflammatory bowel disease by modulating inflammatory factors

Discovery of a novel inhibitor of nitric oxide production with potential therapeutic effect on acute inflammation

Discovery of Novel Sesquistilbene Indanone Analogues As Potent Anti-Inflammatory Agents

Development, synthesis and biological evaluation of imidazole [2,1-b] thiazole derivatives containing an indole ring for their potential anti-inflammatory properties

Synthesis and biological evaluation of chrysin derivatives containing α-lipoic acid for the treatment of inflammatory bowel disease

Design, synthesis and bioactivity evaluation of 4-hydroxycoumarin derivatives as potential anti-inflammatory agents against acute lung injury and colitis

Design, Synthesis, Biological Evaluation and Docking Study of A New Series of 9‐aminoacridine Derivatives as Anti‐inflammatory Agents

Synthesis and Anti-Inflammatory Bowel Disease Activity of Pterostilbene Derivatives